loading...| Preferred Name |
brentuximab vedotin |
|
| Synonyms |
Adcetris |
|
| Definitions |
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66944" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66944" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000530758 |
|
| altLabel |
Adcetris antibody-drug conjugate SGN-35 SGN-35 anti-CD30 antibody-drug conjugate SGN-35 anti-CD30 ADC SGN-35 cAC10-vcMMAE |
|
| CAS Registry |
914088-09-8 |
|
| cui |
C3192355 C1832035 C4760489 C2973446 |
|
| DATE FIRST PUBLISHED |
2007-01-16 |
|
| Date last modified |
2016-05-10 |
|
| definition |
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66944" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66944" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C66944 |
|
| notation |
CDR0000530758 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
brentuximab vedotin |
|
| tui |
T116 T129 T121 |